We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Inverness Medical to Acquire Binax

By Labmedica staff writers
Posted on 17 Feb 2005
Print article
In a move to expand the company's technology base, Inverness Medical Innovations, Inc. (Waltham, MA, USA) has agreed to acquire Binax, Inc. (Portland, ME, USA).

Under the terms of the agreement, Inverness will acquire all of the stock of Binax in exchange for 1.4 million shares of its common stock and additional consideration of U.S.$8.6 million in cash at closing. The agreement also provides for additional consideration to Binax shareholders of up to $11 million in cash contingent upon Binax meeting certain new-product development objectives over five years.

Inverness is a leading global supplier of advanced diagnostic devices and is exploring new opportunities for its proprietary electrochemical and other technologies in a variety of applications, including immuno-diagnostics with a focus on women's health, cardiology, and infectious disease. "We expect to benefit from Binax's established reputation in respiratory diagnostics, and we are excited about the potential new-product development opportunities,” said Ron Zwanziger, CEO of Inverness Medical.

Binax is developing rapid diagnostic kits for the identification of pathogens causing infectious diseases. "By leveraging our combined resources and expertise, we expect to be able to improve our ability to deliver significant and innovative new products to point-of-care diagnostic markets,” remarked Roger Piasio, CEO of Binax.





Related Links:
Inverness
Binax
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.